精密医学:心不全におけるミトコンドリア変異を治療的に標的とする

Alex M Parker¹, Jarmon G Lees², Andrew J Murray³

¹Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia; St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia.

JACC. Basic to translational science

|August 22, 2025

まとめ

心不全 (HF) はミトコンドリア機能障害と酸化ストレスを含みます. ミトコンドリアをターゲットにすることで根源的な原因を解決し患者の治療結果を改善する治療戦略が期待できます

科学分野:

心血管疾患の研究
ミトコンドリア生物学
代謝障害

背景:

心不全 (HF) は,世界全体で6400万人以上の成人に影響し,心血管疾患の負担に大きく貢献しています.
ミトコンドリア機能障害,酸化ストレス,心筋エネルギー障害は,HFの進行と死亡率の主要な要因です.
現在のHF治療は神経ホルモンの経路をターゲットにしていますが,ミトコンドリアの欠陥を直接に対処していません.

研究の目的:

ミトコンドリアの役割に焦点を当てて,HFの進行を促す代謝障害をレビューする.
知識のギャップを特定し,HFにおけるミトコンドリア経路をターゲットにするためのトランスレーション戦略を強調する.
HFに対する新しいミトコンドリア標的治療の課題と最近の進展について議論する.

主な方法:

HFにおける代謝経路とミトコンドリア機能を要約した文献レビュー.
ミトコンドリア標的に関する現在の治療方法とその限界の分析.
ミトコンドリアを標的とした新興戦略とその翻訳的可能性の探索.

主要な成果:

ミトコンドリアの呼吸器の変化と酸化ストレスが,HFの病原性において中心的なものです.
従来のHF治療は,ミトコンドリア機能不全に限られた直接的な利点を提供します.
ミトコンドリアを標的とした治療は新型のHF治療の希望を示しています

結論:

ミトコンドリアを標的とした治療法は,現在の基準を超えてHF治療を進める大きな可能性を秘めています.
代謝障害とミトコンドリア機能障害の対処は,効果的なHF管理に不可欠です.
HFの新たなミトコンドリア治療法の導入における課題を克服するために,さらなる研究と開発が必要である.

キーワード:

心筋病薬物の発見心筋の代謝酸化ストレス薬剤療法呼吸する

さらに関連する動画

11:26

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer

Published on: February 13, 2019

8.8K

09:20

Author Spotlight: Exploring Mitochondrial Function and Chemical Toxicity Using Drosophila melanogaster

Published on: November 10, 2023

1.1K

関連する概念動画

01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

01:46

Electron Transport Chain: Complex I and II

15.0K

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

15.0K

01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

01:26

Heart Failure Drugs: Inotropic Agents

717

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

717

関連する実験動画